| Regulation of HuR structure and function by dihydrotanshinone-I P Lal, L Cerofolini, VG D’Agostino, C Zucal, C Fuccio, I Bonomo, E Dassi, ... Nucleic acids research 45 (16), 9514-9527, 2017 | 78 | 2017 |
| Electrostatic and structural bases of Fe2+ translocation through ferritin channels B Chandramouli, C Bernacchioni, D Di Maio, P Turano, G Brancato Journal of Biological Chemistry 291 (49), 25617-25628, 2016 | 55 | 2016 |
| Interfering with HuR–RNA interaction: design, synthesis and biological characterization of tanshinone mimics as novel, effective HuR inhibitors L Manzoni, C Zucal, DD Maio, VG D’Agostino, N Thongon, I Bonomo, ... Journal of Medicinal Chemistry 61 (4), 1483-1498, 2018 | 50 | 2018 |
| Dual inhibition of PDK1 and Aurora Kinase A: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells S Daniele, S Sestito, D Pietrobono, C Giacomelli, G Chiellini, D Di Maio, ... ACS chemical neuroscience 8 (1), 100-114, 2017 | 49 | 2017 |
| Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: Another tools to fight glioblastoma S Sestito, S Daniele, G Nesi, E Zappelli, D Di Maio, L Marinelli, ... European journal of medicinal chemistry 118, 47-63, 2016 | 25 | 2016 |
| Pathways and Barriers for Ion Translocation through the 5-HT3A Receptor Channel D Di Maio, B Chandramouli, G Brancato PLoS One 10 (10), e0140258, 2015 | 23 | 2015 |
| Understanding the role of dynamics in the iron sulfur cluster molecular machine D di Maio, B Chandramouli, R Yan, G Brancato, A Pastore Biochimica et Biophysica Acta (BBA)-General Subjects 1861 (1), 3154-3163, 2017 | 22 | 2017 |
| Introducing an artificial photo-switch into a biological pore: A model study of an engineered α-hemolysin B Chandramouli, D Di Maio, G Mancini, G Brancato Biochimica et Biophysica Acta (BBA)-Biomembranes 1858 (4), 689-697, 2016 | 16 | 2016 |
| Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence K Bowes, N Jovanoski, AE Brown, D Di Maio, R Belleli, S Chadda, ... Medical Oncology 40 (1), 4, 2022 | 11 | 2022 |
| Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: insights from the SAkura studies M Levy, AR Haycox, U Becker, C Costantino, E Damonte, G Klingelschmitt, ... Multiple Sclerosis and Related Disorders 57, 103332, 2022 | 9 | 2022 |
| Breaking the hydrophobicity of the MscL pore: insights into a charge-induced gating mechanism B Chandramouli, D Di Maio, G Mancini, V Barone, G Brancato PLoS One 10 (3), e0120196, 2015 | 7 | 2015 |
| Indirect treatment comparisons of mosunetuzumab with third-and later-line treatments for relapsed/refractory follicular lymphoma F Bosch, J Kuruvilla, TP Vassilakopoulos, D Di Maio, MC Wei, ... Clinical Lymphoma Myeloma and Leukemia 24 (2), 105-121, 2024 | 6 | 2024 |
| Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing≥ 50% PD-L1: A United Kingdom health care perspective C Yip, A Greystoke, S Abogunrin, R Belleli, D Di Maio, P Rouse, ... Lung Cancer 179, 107171, 2023 | 5 | 2023 |
| The socioeconomic impact of disability progression in multiple sclerosis: a retrospective cohort study of the German NeuroTransData (NTD) registry P Dillon, Y Heer, E Karamasioti, E Muros-Le Rouzic, G Marcelli, D Di Maio, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 9 (3 …, 2023 | 4 | 2023 |
| Best matching protein conformations and docking programs for a virtual screening campaign against SMO receptor G Amendola, D Di Maio, V La Pietra, S Cosconati Molecular Informatics 35 (8-9), 340-349, 2016 | 3 | 2016 |
| Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence N Jovanoski, K Bowes, A Brown, R Belleli, D Di Maio, S Chadda, ... Lung Cancer Management 12 (3), LMT60, 2023 | 2 | 2023 |
| Systematic literature review to identify cost and resource use data in patients with early-stage non-small cell lung cancer (NSCLC) N Jovanoski, S Abogunrin, D Di Maio, R Belleli, P Hudson, S Bhadti, ... PharmacoEconomics 41 (11), 1437-1452, 2023 | 1 | 2023 |
| EE514 A cost-effectiveness analysis of mosunetuzumab for treatment of third-or higher-line relapsed or refractory (R/R) follicular lymphoma (FL) in the United States (US) M Matasar, JS Alvarez, H Parise, E Zuk, D Di Maio, S Shapouri, SW Lin Value in Health 26 (6), S153, 2023 | 1 | 2023 |
| PND55 Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Primary Progressive Multiple Sclerosis D Di Maio, C Liu, G Marcelli, JS Alvarez, J Overell Value in Health 23, S632-S633, 2020 | 1 | 2020 |
| PND47 Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Relapsing Forms of Multiple Sclerosis D Di Maio, C Liu, G Marcelli, JS Alvarez, J Overell Value in Health 23, S631, 2020 | 1 | 2020 |
